Legend Biotech (LEGN) is back in focus after CEO and board member Ying Huang, Ph.D., resigned on July 24, 2026. CARVYKTI business head Alan Bash is stepping in as Interim CEO.

Legend Biotech's share price has come under pressure despite its cell therapy focus, with the 30 day share price return down 34.04% and the 1 year total shareholder return down 51.24%, suggesting momentum has faded as investors reassess execution risk after the CEO change.

If this leadership shake up has you reviewing your biotech exposure, it could be a good moment to look across the sector and see what else is moving through 41 healthcare AI stocks

Legend Biotech still has a lead CAR T therapy, global partners and US$1.14b in revenue. However, the share price has dropped sharply after the CEO exit. Is this a strong business now offered at a mispriced level?

Most Popular Narrative: 64.9% Undervalued

At a last close of $19.05 against a narrative fair value of $54.23, Legend Biotech screens as heavily marked down, with that gap anchored in a detailed set of growth and margin assumptions that investors are now weighing against recent leadership changes.

Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE 5 and 6), and label updates that increase patient access, is setting up long-term revenue acceleration as the patient pool widens. Increasing international penetration with recent launches in multiple European and global markets, supported by ongoing manufacturing expansion and supply chain optimization, is expected to materially broaden Legend's total addressable market and improve gross and net margins as production scales.

Want to see what sits behind that growth story for Legend Biotech? The narrative focuses on ambitious revenue compounding, margin expansion and a richer earnings profile that are framed as far from conservative.

Result: Fair Value of $54.23 (UNDERVALUED)

However, the Legend Biotech story also carries significant pressure points, including heavy reliance on CARVYKTI along with ongoing losses, with net income at a loss of US$250.1 million.

Next Steps

With Legend Biotech sitting at the center of both concern and optimism, this is a good moment to review the data yourself and move quickly. To see both sides of the story in one place, take a closer look at the 3 key rewards and 1 important warning sign

Looking for more Legend Biotech sized investment ideas?

If this Legend Biotech update has you rethinking your watchlist, do not stop here. Use the Simply Wall Street Screener to uncover focused ideas that match your approach.

• Spot potential mispricing early by scanning companies that currently appear out of favour through the 57 high quality undervalued stocks.
• Strengthen your downside protection by zeroing in on businesses highlighted in the 89 resilient stocks with low risk scores.
• Hunt for off-the-radar opportunities with solid fundamentals by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.